Abstract | Frontotemporal dementia (FTD) is a clinical syndrome with a heterogeneous molecular basis. Until recently, the underlying cause was known in only a minority of cases that were associated with abnormalities of the tau protein or gene. In 2006, however, mutations in the progranulin gene were discovered as another important cause of familial FTD. That same year, TAR DNA-binding protein 43 (TDP-43) was identified as the pathological protein in the most common subtypes of FTD and amyotrophic lateral sclerosis (ALS). Since then, substantial efforts have been made to understand the functions and regulation of progranulin and TDP-43, as well as their roles in neurodegeneration. More recently, other DNA/RNA binding proteins (FET family proteins) have been identified as the pathological proteins in most of the remaining cases of FTD. In 2011, abnormal expansion of a hexanucleotide repeat in the gene C9orf72 was found to be the most common genetic cause of both FTD and ALS. All common FTD-causing genes have seemingly now been discovered and the main pathological proteins identified. In this Review, we highlight recent advances in understanding the molecular aspects of FTD, which will provide the basis for improved patient care through the development of more-targeted diagnostic tests and therapies.
Introduction
Frontotemporal dementia (FTD) accounts for 5-15% of all cases of dementia, and is the second most common cause of dementia in the presenile age group (<65 years of age).
1,2 FTD is a clinical syndrome that is characterized by progressive deterioration in behaviour, personality and/or language, with relative preservation of memory. [3] [4] [5] Clinical subtypes of FTD include the behavioural variant (bvFTD) and two forms of primary progressive aphasia: progressive nonfluent aphasia (PNFA) and semantic dementia. Additionally, FTD is often associated with an extra pyramidal movement disorder (parkinsonism or cortico basal syndrome) and/or motor neuron disease. 6, 7 Given this variability in phenotype, it is not surprising that the molecular basis of FTD is also heterogeneous ( Table 1) .
A family history of FTD, often showing an autosomal dominant pattern of inheritance, is present in 25-50% of cases, indicating a strong genetic component. 8, 9 In 1998, mutations in the microtubule-associated protein tau (MAPT) gene on chromosome 17 were identified in a number of families with FTD and parkinsonism. [10] [11] [12] Since then, 44 different MAPT mutations have been reported, accounting for 5-20% of cases of familial FTD. 13, 14 However, a number of chromosome 17-linked FTD f amilies remained in whom no MAPT mutations were found.
A major breakthrough occurred in 2006 when the progranulin (GRN) gene was identified as the second FTD-related gene on chromosome 17. 15, 16 Indeed, GRN mutations account for an even larger proportion of FTD families than do mutations in MAPT. 13 Much less common are mutations in the valosin-containing protein (VCP) gene, which cause the rare familial syndrome of inclusion body myopathy with Paget disease of bone and FTD, 17 and a mutation in the gene encoding charged multi vesicular body protein 2B (CHMP2B), which was found in a large Danish FTD pedigree. 18 In addition, several families with a combination of FTD and amyotrophic lateral sclerosis (ALS) have been reported to have genetic linkage to a locus on chromosome 9p. [19] [20] [21] [22] [23] [24] [25] [26] [27] Despite years of intense effort by many research groups worldwide, the identity of the FTD-ALS gene on chromosome 9p remained elusive until 2011, when two independent studies identified the defect as being an expanded hexanucleotide repeat in a non coding region of the chromo some 9 open reading frame 72 (C9orf72) gene. 28, 29 Discovery of the C9orf72 mutation has generated tremendous excitement in the FTD and ALS research communities, as it seems to be the most common genetic cause of both conditions.
The neuropathology associated with clinical FTD is also heterogeneous. 30 A common feature of this disease is the relatively selective degeneration of the frontal and temporal lobes, and the term 'frontotemporal lobar degeneration' (FTLD) is often used for pathological conditions that predominantly or commonly present with FTD. In addition, most cases of FTLD are found to have abnormal intra cellular accumulation of a disease-specific protein; as a result, classification of FTLD into broad categories on the basis of the molecular defect thought to be most characteristic of the disease has become a popular approach. 31, 32 Initially, only the FTLD subgroup characterized by the aggregation of hyperphosphorylated tau protein in neurons and glia, classified as FTLD-tau, was well-understood (Table 1) . However, most cases of FTD are not associated with tau pathology, but are instead charac terized by neuronal inclusions that were originally identified using immuno histochemistry for ubiquitin -these cases were consequent ly termed FTLD-U. 33, 34 Just months after publication of the studies in which the GRN mutations were discovered, another landmark paper reported TAR DNA-binding protein as the ubiquitinated pathological protein in most cases of FTLD-U (subsequently renamed FTLD-TDP), as well as in the majority of ALS cases. 35, 36 This finding provided FTLD-FUS) . [39] [40] [41] More recently, the FUS-positive inclusions in FTLD-FUS were found to also stain positively for other members of the FET family of DNA/RNA-binding proteins, including Ewing sarcoma protein (EWS) and TATA-binding protein-associated factor 15 (TAF15). 42 Over the past few years, the pace at which our knowledge of the molecular genetics and neuropathology of FTD has advanced has been truly remarkable (Box 1). In just over 5 years, we have gone from knowing virtually nothing of the molecular basis of most cases of FTD, to now being able to determine the genetic cause in the majority of autosomal dominant families, and being able to assign virtually all cases of FTLD to one of three major pathological subtypes: FTLD-tau, FTLD-TDP or FTLD-FUS. 32 This insight is a crucial step towards improved care for patients with FTD, as it provides the basis for moreinformed counselling and the potential for more-specific diagnostic tests and targeted therapies. In this Review, we highlight several recent advances in our understanding of the molecular aspects of FTD, focusing on the discovery of the C9orf72 mutation and the roles of progranulin, TDP-43, and FUS and the other FET proteins in disease pathogenesis. 13, 43 Progranulin is a multi functional secreted growth factor that is expressed by many cell types including neurons. 44 Pathogenic mutations in GRN are of various types and occur throughout the gene, but all cause disease via haplo insufficiency. 15, 16 As a result, substantially reduced levels of pro granulin protein are consistently observed in plasma, serum and cerebrospinal fluid samples from symptomatic and asymptomatic GRN mutation carriers. [45] [46] [47] On the basis of these findings, ELISAs to measure levels of pro granulin are being developed as an inexpensive alternative to classic sequencing analyses for diagnostic testing of patients with FTD.
Genetic modifiers and regulators of GRN expression
The clinical phenotype associated with GRN mutations is variable [48] [49] [50] [51] [52] [53] and penetrance is incomplete. 54 Understanding the factors that modify the expression of GRN mutations or regulate the normal GRN gene is of potential therapeutic importance. One such genetic factor is variation in the uncharacterized trans membrane protein 106B (TMEM106B) gene, which was recently uncovered in a genome-wide association study (GWAS) of patients with known FTLD-TDP pathology. 55 Genetic variants in and near TMEM106B seem to protect from-or delay the onset of-FTD in indivi duals with pathogenic GRN mutations, possibly by increasing the levels of pro granulin. [55] [56] [57] [58] A number of microRNAs, including miR-29b and miR-107, have also been implicated in GRN regulation. 59, 60 In addition, the minor T allele of genetic variant rs5848 (located in the 3' untranslated region of GRN) was found to increase the binding of miR-659 to GRN, thereby reducing the levels of progranulin. 61 Genetic association studies have shown that carriers who are homozygous for the T allele of rs5848 have a threefold increased risk of develop ing FTLD-TDP compared with homozygous C-allele carriers, 61 supporting a role for progranulin in sporadic FTD and possibly other neuro degenerative disease s such as Alzheimer disease. [62] [63] [64] GRN expression may also be modified by exogenous factors. GRN transcription was shown to be enhanced by small molecules such as suberoylanilide hydroxamic acid, 65 whereas inhibitors of the vacuolar ATPase, and some alkalizing drugs, increased progranulin production and secretion through a translational mechanism. 66 Cellular biology of progranulin Substantial progress has been made in recent years towards our understanding of progranulin biology and the neuroprotective function of this protein. Addition of progranulin to stressed or progranulin-depleted neuronal cells promotes neurite outgrowth. [67] [68] [69] [70] The neuroprotective effects of progranulin might be attributable, at least in part, to the activation of cell signalling pathways involved in cell survival, 67, [71] [72] [73] [74] and a role for progranulin in excitotoxicity and synaptic transmission has also been suggested. 69, 75 Importantly, sortilin (SORT1), a receptor for neurotrophic factors in the brain, was identified in two independent studies as the first known receptor for progranulin. 76, 77 SORT1 has been shown to mediate pro granulin endocytosis and regulate the levels of progranulin in vivo in mouse brain and in human plasma. Another study, published in 2011, reported that tumour necrosis factor receptors directly interact with progranulin. 78 The identification of progranulin receptors is exciting, as it opens new avenues in progranulin cell biology research and provides another potential route to FTD therapy.
C9orf72 mutation
Since 2006, increasing evidence has suggested the presence of a major locus for the combined phenotype of FTD and ALS on chromosome 9p21, but the disease mutation remained elusive (Box 2). [19] [20] [21] [22] [23] [24] [25] [26] [27] The key to the identification of the disease-causing mutation was the observation of non-Mendelian inheritance of a GGGGCC hexanucleotide repeat located in a noncoding region of C9orf72 ( Figure 1a ) in a large FTD-ALS family designated VSM-20 (Vancouver, San Francisco and Mayo family 20). 28 Using primers that flanked the repeat region, researchers discovered that all affected indivi duals in this family appeared homozygous by fluorescent PCR, yet affected children did not seem to inherit an allele from their affected parent. This finding suggested the presence of a repeat expansion that was too large to be amplified by the PCR method, a suspicion that was confirmed using a repeat-primed PCR assay ( Figure 1b) and Southern blot analysis. The polymorphic nature of this GC-rich hexanucleotide repeat was independently recognized by means of next-generation sequencing in a Welsh family with FTD-ALS, 29 further implying a role for this genomic region in disease pathogenesis.
Mutation frequency
In the 6 months since discovery of the C9orf72 mutation, numerous FTD and ALS patients have been screened using the repeat-primed PCR assay for the presence of GGGGCC repeat expansions in C9orf72 (Table 2) . 28, 29, [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] Mutation frequency has varied substantially among populations, with the highest frequency observed in genetically isolated populations from Finland and Sardinia, and in cohorts where all patients had a pathological diagnosis of FTLD-TDP (with or without ALS). 28, 29, 82, 86, 89 The average mutation frequencies reported in North American and European populations are 37% for familial ALS, 6% for sporadic ALS, 21% for familial FTD, and 6% for sporadic FTD patients. In all series, the C9orf72 mutation is the most common genetic cause of familial ALS (more frequent than superoxide dismutase 1 mutations) and is comparable in frequency to GRN mutations in FTD families. To date, most of the patients included in the mutation screenings have been white; however, C9orf72 repeat expansions have also been identified in patients of African American, Middle Eastern and Asian race. 87, 89, 95 Interestingly, independent of clinical presentation or ethnic origin, all C9orf72 mutation carriers inherit the expansion on the same genetic background, suggesting the presence of a common ancestor or, alternatively, the occurrence of multiple independent expansions on a fragile predisposing disease haplotype. 89, 96, 97 Clinical phenotypes Several groups from North America and Europe have published descriptions of the demographic, clinical and neuropathological features of their cohorts with the C9orf72 mutation. 28, 29, [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] The clinical presentation of patients with this mutation is heterogeneous and highly variable between and within families. Patients may present with FTD, ALS or features of both. The FTD subtype is most often bvFTD, with PNFA being observed less frequently. ALS typically shows early involvement of both upper and lower motor neurons, and bulbar presentation is particularly common. 80, 82, 83, 95 Several studies have found that ALS patients with the C9orf72 mutation have a slightly earlier onset and shorter disease duration than those without the mutation. 80, 82, 83, 85, 92, 95 In addition to FTD and ALS, other features in patients with the mutation can include memory disorder, 79, 86, 88, 91, 93, 94 psychosis, 79, 84, 86, 93, 94 extrapyramidal movement disorder (usually an akinetic-rigid syndrome) 79, 83, 84, 86, 91, 93 and cere bellar signs. 86 Symptoms tend to accumulate and phenotypes converge with disease progression, with most patients eventually developing some abnormalities of behaviour, language and motor function. 79, 81, 83, 86, 95 Wide variation exists in the age at onset (27-83 years, mean ~50 years) and disease duration (1-22 years), and several studies have noted earlier disease onset in subsequent generations, consistent with the phenomenon of genetic anticipation. 79, 82, 83, 85, 86, 95 Assessment of patients with the C9orf72 mutation by means of structural neuroimaging tends to show symmetrical bilateral atrophy, primarily affecting frontotemporal regions, but also involving other cerebral lobes and the cerebellum. 79, 86, 88, 93, 98 Neuropathology The neuropathology associated with the C9orf72 mutation is a combination of FTLD-TDP and classic ALS. 28, 79, 80, 83, 85, 86, 88, 91, [93] [94] [95] 99, 100 Regardless of the clinical pheno type, postmortem examination usually shows TDP-43-positive inclusions in a wide range of neuroanatomical regions, including the extramotor cerebral cortex, hippocampus, basal ganglia, substantia nigra, and lower motor neurons of the brainstem and spinal cord. In addition, a unique and highly characteristic feature of patients with the mutation is the presence of neuronal inclusions in the cerebellar granule cell layer, hippo campal pyramidal neurons and other neuroanatomical sites that stain positively for proteins of the ubiquitin proteasome system (such as ubiquitin, ubiquilins and p62) but are negative for TDP-43 ( Figure 1c) . 28, 79, 80, 83, 85, 86, 88, 91, [93] [94] [95] 99, 100 This consistent finding suggests that the mutation causes abnormal metabolism and accumulation of one or more as yet unidentified molecules, which could include mutant RNA or RNA-binding proteins, or protein products of aberrant splicing. To date, immunohistochemical studies using commercial antibodies against C9orf72 have failed to demonstrate any abnormal distribution or ac cumulation of this protein. 28, 80, 83, 86, 88, 94, 95 Repeat size All C9orf72 mutation screenings performed thus far have used the repeat-primed PCR method to detect the presence of a pathogenic GGGGCC repeat expansion. However, it is important to note that this method is only semiquantitative and that the characteristic stutter pattern . [19] [20] [21] [22] [23] [24] [25] [26] [27] The minimal candidate region shared by all families was a 3.7 Mb region containing only 10 known or predicted genes. In 2010, three GWAS in sporadic ALS populations identified a novel susceptibility locus on chromosome 9p that completely overlapped with the candidate region for familial FTD-ALS. [157] [158] [159] The strongest association was found in an ~80 kb haplotype block containing only three genes: MOBKL2B, IFNK and C9orf72. An independent GWAS in patients with pathologically confirmed FTLD-TDP nominated the same chromosomal region, implicating the chromosome 9p gene defect in sporadic forms of both FTD and ALS. 55 However, despite concerted efforts by the FTD and ALS research communities, in-depth candidate-gene sequencing and targeted next-generation sequencing of the minimal candidate region failed to identify the causative mutation, suggesting that a complex mutational mechanism may be involved. In 2011, an expanded hexanucleotide repeat in the noncoding region of C9orf72 was found to be the long-sought-after cause of FTD and ALS on chromosome 9p. 28, 29 Abbreviations: ALS, amyotrophic lateral sclerosis; FTD, frontotemporal dementia; GWAS, genome-wide association studies.
on PCR (Figure 1b ) cannot be used to determine the exact number of repeats. In one family, Southern blot analyses performed using DNA extracted from lymphoblast cell lines showed pathogenic repeat expansions of 700-1,600 repeat units; 28 however, the minimal repeat size required for disease manifestation may be consider ably smaller. As in other noncoding repeat expansion disorders, evidence for somatic instability of the C9orf72 repeat exists. 28 Consequently, repeat lengths may vary among different tissues within the same individual, making it difficult to accurately size the repeat and determine correlations between genetics, clinical presentation and pathology. [101] [102] [103] Combined with the aforementioned technical challenges, our lack of knowledge of the minimal pathogenic repeat size raises important questions regarding genetic testing for this common mutation, particularly in the context of predictive genetic testing. Accurate sizing of the expanded repeat in large FTD and ALS patient series will be crucial to establish a reliable cut-off size, which will assist when counselling individuals who are under going genetic testing. Future studies should also determine whether the repeat length contributes to the variability in onset age and clinical presentation, or whether other genetic and/or environmental modifiers are involved.
Disease mechanism
C9orf72 is a completely uncharacterized protein, the function of which is unknown. Two different isoforms of the protein are predicted to be generated from a total of three different C9orf72 transcripts; 28 however, the relative expression of each of these transcripts in individual brain regions has not been studied. Several groups have shown ~50% loss of at least one C9orf72 transcript in expandedrepeat carriers, presumably owing to interference of the expanded GC-rich repeat with C9orf72 transcription regulation. 28, 29, 85 Although these findings support a possible loss-of-function disease mechanism, the accumulation of transcripts containing the GGGGCC repeat as nuclear RNA foci in the frontal cortex and spinal cord of C9orf72 mutation carriers has also been demon strated (Figure 1d) , suggesting a possible toxic RNA gain-offunction disease mechanism. 28 On the basis of current knowledge of the pathogenesis of other noncoding repeat expansion disorders, one might suggest that these RNA foci will alter the function of one or more RNA-binding proteins, resulting in downstream changes in gene expression and/or alternative splicing of a range of transcripts. human C9orf72 containing expanded GGGGCC repeats, are currently being generated to determine the contribution of each disease mecha nism to neurodegeneration and TDP-43 aggregation.
Other genes and genetic risk factors
FTD-related genes
With the identification of the repeat expansion in C9orf72, we have now accounted for all previously published FTD families with genome-wide linkage. Although it is unlikely that any other common FTD-related genes exist, rare mutations in other genes could explain a small number of the remaining families. Combinations of genetic variants and environmental factors are likely to be responsible for disease in the majority of patients with sporadic FTD.
The use of whole-exome sequencing and whole-genome sequencing will greatly facilitate the discovery of rare genetic defects in the future, as was recently demonstrated with the identification of mutations in the colony stimulating factor 1 receptor gene as the cause of hereditary diffuse leukoencephalopathy with spheroids, 105 a disorder with variable clinical presentation that includes features of FTD. Additional GWAS-such as a large collaborative study that is currently underway, which includes more than 2,500 samples from patients with FTD-may identify additional genetic risk factors.
ALS-related genes
Other rare genetic causes of FTD that have been identified in recent years include TARDBP and FUS, although The geographical origin of the Asian patients was not reported in detail; however, the familial ALS patient carrying the C9orf72 repeat expansion was Japanese. Abbreviations: ALS, amyotrophic lateral sclerosis; C9orf72, chromosome 9 open reading frame 72; FTD, frontotemporal dementia; NA, not applicable; NS, not stated. mutations in each of these genes usually cause a pure ALS phenotype. 37, 38, 106, 107 In 2011, UBQLN2, a gene that encodes a member of the ubiquilin family, which is involved in the degradation of ubiquitinated proteins, was also added to the list of ALS-FTD-related genes. 108 Progressive dementia with abnormalities in both behaviour and executive functions were reported in ~20% of UBQLN2 mutation carriers; however, none of these patients presented with FTD alone.
Advances in molecular pathology
TDP-43 TDP-43 is a highly conserved, predominantly nuclear protein that can shuttle between the nucleus and cytoplasm. This protein has a number of well-described functions in RNA regulation, such as the control of splicing, and in mRNA transport and stability; however, the full complexity of TDP-43 function is only just emerging.
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FTLD-TDP
Abnormal accumulation of TDP-43 in neuronal and glial inclusions is the characteristic neuropathological feature in ~50% of patients with FTD (a condition termed FTLD-TDP) and in the vast majority of ALS cases. 31, 35, 36 Pathological modifications of TDP-43 in these disorders include a redistribution of the protein from the nucleus to the cytoplasm in cells with inclusions, as well as hyperphosphorylation, ubiquitination and N-terminal truncation of the protein. 36 FTLD-TDP includes sporadic and genetic forms, with mutations having been identified in GRN, VCP and TARDBP, along with the recently recognized C9orf72 repeat expansion (as described above). 28, 29, [112] [113] [114] [115] On the basis of the morphology and anatomical distribution of TDP-43 pathology, four distinct FTLD-TDP subtypes can be recognized. [116] [117] [118] The relevance of this heterogeneity is supported by clinical and genetic correlations (Table 1) , as well as by emerging evidence for distinct biochemical properties of TDP-43 in the different subtypes.
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Pathogenesis of TDP-43 proteinopathies
The neuropathological findings in patients with FTLD-TDP implicate both loss-of-function and gain-offunction mechanisms in TDP-43-associated cell death. Numerous research groups worldwide are focused on addressing these mechanisms, and detailed discussions of TDP-43 pathogenesis have been published elsewhere. [120] [121] [122] Briefly, current in vivo models provide evidence for both scenarios: neither reduced nor increased expression of the tightly autoregulated TDP-43 protein is well-tolerated. [120] [121] [122] However, no model has fully recapitu lated the neuropathological and biochemical features of human TDP-43 related diseases. Although the presence of TARDBP mutations is a clear indicator that dysfunction of TDP-43 is directly linked to neurodegeneration, the functional consequences of TARDBP mutations are still unresolved. No solid evidence that TARDBP mutations act through a toxic gain-of-function mechanism exists, and no functional consequences of TARDBP mutations on the processing of selected RNA targets have been reported. However, studies that used crosslinking immuno precipitation and high-throughput sequencing have identified more than 6,000 RNA targets of TDP-43. indivi dual pathways that are regulated by TDP-43, and to identify possible disease-relevant RNA targets. Another important but unresolved issue is the role of TDP-43 in the non-TARDBP-associated genetic forms of FTLD-TDP. The fact that disease associated with mutations in GRN, VCP or C9orf72 is consistently characterized by the presence of TDP-43 pathology suggests that dysregulation of TDP-43 might be a crucial common downstream mechanism leading to cell death in each of these disorders. However, the relevance of TDP-43 accumulation in C9orf72 mutation carriers has recently been challenged by the identification of TDP-43-negative, ubiquitin-positive pathology that is more abundant than the TDP-43 pathology in distinct brain regions (Figure 1c) , raising the possibility that, in these cases, another unidentified protein-or proteins-might be more important than TDP-43 in the pathogenesis. 28, 79, 80, 83, 85, 86, 88, 91, [93] [94] [95] 99, 100 FUS and other FET proteins FUS belongs to the FET protein family, which also includes EWS, TAF15, and the Drosophila orthologue of FUS, Cabeza. These proteins are highly conserved, ubiquitously expressed, predominantly nuclear (Figure 2a) , multifunctional DNA/RNA-binding proteins 123 that can bind to a large number of partially overlapping RNA targets. 124 
FTLD-FUS
Early in 2009, FUS mutations were reported to be the cause of ~3% of familial ALS cases in which the associated pathology was characterized by FUS-positive, TDP-43-negative inclusions. 37, 38 These cases were consequently termed ALS-FUS. Subsequently, FUS was found to be the most characteristic marker for the pathology in many of the remaining tau/TDP-negative FTLD cases, which include three closely related but distinct clinicopathological entities: atypical FTLD-U (aFTLD-U), neuronal intermediate filament inclusion disease, and basophilic inclusion body disease. [39] [40] [41] 125 The identification of FTLD-FUS as a new molecular subgroup 32 provided further evidence that FTD and ALS are closely related conditions, and emphasized the pathogenic role of RNAbinding proteins in these disorders. However, despite some overlap in the phenotype and pathological features of FTLD-FUS and ALS-FUS, marked differences were also observed. 126, 127 Moreover, after additional cases were reported, it became evident that ALS with FUS pathology is almost always caused by a FUS mutation, whereas cases of FTLD-FUS tend to be sporadic, with none yet associat ed with a genetic abnormality of FUS. [39] [40] [41] 125 Further evidence for different pathomechanisms in the two disorders was provided via a study that investigated FET protein members (other than FUS) in a series of ALS-FUS and FTLD-FUS cases. 42 In ALS-FUS with a range of different mutations, no co-accumulation of other FET proteins into FUS-positive inclusions was found, with only nuclear staining of TAF15 and EWS being observed (Figure 2b) . In striking contrast, in all FTLD-FUS subtypes, TAF15 and EWS were found to co-accumulate in FUS-positive cytoplasmic inclusions, and inclusion-bearing cells showed reduced levels of nuclear staining of all three FET proteins, particularly TAF15 (Figure 2c ).
The addition of TAF15 and EWS to the growing list of neurodegeneration-associated RNA-binding proteins is further supported by studies in which TAF15 was identified as a candidate through a yeast functional screen to identify RNA binding proteins with similar function to TDP-43 and FUS. 128 Descriptions of genetic variants (of undetermined pathogenic relevance) in TAF15 and EWSR1 in a small number of ALS cases provide further evidence for a role for these proteins in neurodegeneration. 129, 130 Although the roles of FUS, TAF15 and EWS in FTLD-FUS remains to be elucidated, the term FTLD-FET now seems more appropriate for this molecular FTLD subgroup.
Pathogenesis of FUS proteinopathies
The differences in the molecular pathology of ALS-FUS and FTLD-FUS imply that different pathological processes underlie inclusion formation and cell death in each disorder: ALS-FUS might be restricted to dysfunction of FUS, whereas FTLD-FUS may involve dysfunction of all FET proteins ( Figure 2) .
In ALS-FUS, mutations in the C-terminus of the FUS protein disrupt a region characterized as a nonclassical nuclear localization sequence. This disruption leads to impaired transportin-mediated nuclear import of FUS, with redistribution of the protein to the cytoplasm (Figure 2b) . 131, 132 Importantly, localization of other FET proteins is not altered under these conditions. 42 The degree of impairment in FUS nuclear transport varies among different FUS mutations, but correlates with the observed variability in disease course associated with different mutations, and with distinct pathological patterns of ALS-FUS pathology. 126 This finding provides strong evidence that impaired nuclear import of FUS is a key event in ALS-FUS disease pathogenesis.
In FTLD-FUS, a more general defect of transportinmediated nuclear import that affects the distribution of all FET proteins is postulated, with two plausible scenarios (Figure 2c ). First, a primary defect of transportin itself, resulting either from genetic variations in the transportin gene (TNPO1) or from post-translational modifications or altered expression levels of transportin protein, could lead to reduced efficiency of nuclear import of all FET proteins. In this scenario, however, one might also expect alterations in the subcellular distribution of other transportin cargos such as hnRNPA1, which has not been supported by preliminary data. 42 Second, the normal nuclear import of FET proteins might be affected by abnormal post-translational modifications of FET proteins, such as arginine methyla tion or phos phorylation, which have been shown to modulate nucleocytoplasmic transport, proteinprotein interaction and protein stability. 123, [133] [134] [135] [136] [137] [138] [139] So far, bio chemical analysis of protein extracted from FTLD-FUS brains has revealed increased insolubility of all FET proteins, without other obvious disease-associated changes such as truncation or abnormal phosphorylation; 40, 42, 140 however, more-detailed biochemical analyses are required.
The downstream effects of redistribution of FUS or all FET proteins in the pathogenesis of ALS-FUS and FTLD-FUS, respectively, have not been determined. As in the case of TDP-43, either a gain of toxic properties or a loss of function owing to sequestration of these proteins in aggregates is plausible. Results from initial in vivo models of ALS-FUS have been inconsistent and the mechanisms remain unresolved. 122, 141 Molecular correlates of FTD phenotypes Each of the molecular subtypes of FTLD pathology is associated with a range of clinical features and may be caused by defects in specific genes (Table 1) . However, prediction of the underlying molecular pathology or genetics on the basis of pattern of inheritance and clinical features is often imprecise. 142, 143 Semantic dementia is usually sporadic and associated with FTLD-TDP type C, with fewer cases having the pathology of classical Pick disease. Cases of sporadic PNFA are more likely to have FTLD-tau than FTLD-TDP, but bvFTD can be associated with any of the major pathologies. Early-onset bvFTD with severe psycho behavioural abnormality, but with minimal motor features or aphasia, is characteristic of the aFTLD-U subtype of FTLD-FUS. When FTD is combined with ALS, the pathology is usually FTLD-TDP, whereas FTD with prominent parkinsonism is more often FTLD-tau (namely, progressive supranuclear palsy or cortico basal degeneration). In families with autosomal dominant inheritance of bvFTD or PNFA without marked motor dysfunction, the underlying gene defect may be a mutation in C9orf72, GRN or MAPT. When parkinsonism or primary lateral sclerosis are also prominent features, a MAPT mutation is more likely, whereas coexistence of classical ALS in a family strongly suggests a C9orf72 mutation. Further research is required to improve our understanding of the correlation between molecular basis and clinical phenotypes of the different FTD subgroups.
Conclusions and future directions
The past 6 years have seen remarkable progress in our understanding of the molecular basis of FTD. Apparently, all common FTD-causing genes have now been discovered and the major pathological proteins identified. Although many aspects of specific pathogenic mechanisms remain to be resolved, we are already in a position to begin translating this newly acquired knowledge into improved patient care. The recent discoveries of mutations in GRN and C9orf72 will enable more-informed genetic counselling, and our improved knowledge of the pathological proteins in FTD is driving attempts to develop diseasespecific, molecular-based diagnostic tests, such as the quantification of total or pathological protein species in biofluids. 144, 145 Recognition of progranulin insufficiency as an important patho mechanism in familial FTD and some sporadic forms of FTD, combined with improved understanding of progranulin regulation and cell biology, has already led to initial plans for progranulin-based clinical trials. 146 The identification of a role for TDP-43, FET proteins and C9orf72 in FTD has opened up new avenues of research related to RNA regulation. Finally, a greater appreciation of the overlap between FTD and ALS is now bringing research and patient care in these disorders closer together. Hopefully, patients with FTD will soon ex perience real benefits from these and future advances.
